Trypanocidal properties, structure-activity relationship and computational studies of quinoxaline 1,4-di-N-oxide derivatives

Experimental Parasitology

Volumn 127, Issue 4, 2011, Pages 745-751

  Estevez, Yannick ^a   Quiliano, Miguel ^b   Burguete, Asunción ^c   Cabanillas, Billy ^a,b,d   Zimic, Mirko ^b   Málaga, Edith ^b   Verástegui, Manuela ^b   Pérez Silanes, Silvia ^c   Aldana, Ignacio ^c   Monge, Antonio ^c   Castillo, Denis ^b   Deharo, Eric ^a,d  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^c UNIVERSITY OF NAVARRA   (Spain)

^d INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Peru)

Author keywords

Leishmania peruviana; Quinoxaline 1,4 di N oxide derivatives; Trypanosoma cruzi

Indexed keywords

1 (7 FLUORO 3 METHYL QUINOXALIN 2 YL) 3 (3,4,5 TRIMETHOXYPHENYL)PROPENONE; 2,6 DIMETHYL 3 F QUINOXALINE 1,4 DIOXIDE; 3 (3,4,5 TRIMETHOXYPHENYL) 1 (3,6,7 TRIMETHYL QUINOXALIN 2 YL)PROPENONE; AMPHOTERICIN B; ANTITRYPANOSOMAL AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTOZOAL PROTEIN; QUINOXALINE 1,4 OXIDE DERIVATIVE; TRIMETHOXYPHENYL PROPENONE; TRIMETHOXYPHENYL PYRAZOLE QUINOXALINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; KIDNEY CELL; LEISHMANIA; LEISHMANIA PERUVIANA; MATHEMATICAL COMPUTING; MOLECULAR DOCKING; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA CRUZI;

ANIMALS; CERCOPITHECUS AETHIOPS; FEMALE; LEISHMANIA; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; QUINOXALINES; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI; VERO CELLS;

LEISHMANIA PERUVIANA; MURINAE; TRYPANOSOMA CRUZI;

EID: 79952360113     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2011.01.009     Document Type: Article

References (41)

1. Alarcón de la Lastra C., Villegas I., Sánchez-Fidalgo S. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications. Current Pharmaceutical Design 2007, 13:933-962.
2. Aponte J.C., Verastegui M., Malaga E., Zimic M., Quiliano M., Vaisberg A.J., Gilman R.H., Hammond G.B. Synthesis, cytotoxicity, and anti-Trypanosoma cruzi activity of new chalcones. Journal of Medicinal Chemistry 2008, 51:6230-6234.
3. Arnold K., Bordoli L., Kopp J., Schwede T. The SWISS-MODEL workspace. a web-based environment for protein structure homology modelling. Bioinformatics 2006, 22:195-201.
4. Burguete A. Design, synthesis and biological evalulation of new quinoxaline and quinoxaline 1,4-di-N-oxide derivatives with application in different therapeutic areas 2010, Universidad de Navarra Spain, Pamplona.
5. Burguete A., Estevez Y., Castillo D., Gonzalez G., Villar R., Solano B., Vicente E., Silanes S.P., Aldana I., Monge A., Sauvain M., Deharo E. Anti-leishmanial and structure-activity relationship of ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives. Memórias do Instituto Oswaldo Cruz 2008, 103:778-780.
6. Burguete A., Pontiki E., Hadjipavlou-Litina D., Villar R., Vicente E., Solano B., Ancizu S., Perez-Silanes S., Aldana I., Monge A. Synthesis and anti-inflammatory/antioxidant activities of some new ring substituted 3-phenyl-1-(1, 4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives and of their 4, 5-dihydro-(1H)-pyrazole analogues. Bioorganic & Medicinal Chemistry Letters 2007, 17:6439-6443.
7. Castillo D., Arevalo J., Herrera F., Ruiz C., Rojas R., Rengifo E., Vaisberg A., Lock O., Lemesre J.L., Gornitzka H., Sauvain M. Spirolactone iridoids might be responsible for the antileishmanial activity of a Peruvian traditional remedy made with Himatanthus sucuuba (Apocynaceae). Journal of Ethnopharmacology 2007, 112:410-414.
8. Costantino G., Macchiarulo A., Camaioni E., Pellicciari R. Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis. Journal of Medicinal Chemistry 2001, 44:3786-3794.
9. Cunico W., Gomes C.R., Facchinetti V., Moreth M., Penido C., Henriques M.G., Varotti F.P., Krettli L.G., Krettli A.U., Da Silva F.S., Caffarena E.R., De Magalhães C.S. Synthesis, antimalarial evaluation and molecular modeling studies of hydroxyethylpiperazines, potential aspartyl protease inhibitors, part 2. European Journal of Medicinal Chemistry 2009, 44:3816-3820.
10. Davis A.J., Murray H.W., Handman E. Drugs against leishmaniasis: a synergy of technology and partnerships. Trends in Parasitology 2004, 20:73-76.
11. Dundas J., Ouyang Z., Tseng J., Binkowski A., Turpaz Y., Liang J. CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Research 2006, 34:116-118.
12. Ertl P., Rohde B., Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. Journal of Medicinal Chemistry 2000, 43:3714-3717.
13. Fernandez Villamil S.H., Baltanas R., Alonso G.D., Vilchez Larrea S.C., Torres H.N., Flawia M.M. TcPARP: a DNA damage-dependent poly(ADP-ribose)polymerase from Trypanosoma cruzi. International Journal for Parasitology 2008, 38:277-287.
14. Gonzalez G., Castillo D., Estevez Y., Grentzinger T., Deharo E. Leishmania (Viannia) peruviana (MHOM/PE/LCA08): comparison of THP-1 cell and murine macrophage susceptibility to axenic amastigotes for the screening of leishmanicidal compounds. Experimental Parasitology 2009, 122:353-356.
15. Gordon L.F. Substituent constants for correlation analysis in chemistry and biology. By Corwin Hansch and Albert Leo. Wiley, 605 Third Ave., New York, NY 10016. 1979. 339 pp. 21 × 28 cm. Journal of Pharmaceutical Sciences 1980, 69:1109.
16. Guex N., Peitsch M.C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997, 18:2714-2723.
17. Hattori K., Kido Y., Yamamoto H., Ishida J., Kamijo K., Murano K., Ohkubo M., Kinoshita T., Iwashita A., Mihara K., Yamazaki S., Matsuoka N., Teramura Y., Miyake H. Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly (ADP-ribose) polymerase. Journal of Medicinal Chemistry 2004, 47:4151-4154.
18. Hess B., Kutzner C., van der Spoel D., Lindahl E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. Journal of Chemical Theory and Computation 2008, 4:435-447.
19. Hooft R.W., Vriend G., Sander C., Abola E.E. Errors in protein structures. Nature 1996, 381:272.
20. Hypercube, HyperChem 7.5, Ontario.
21. Ishida J., Yamamoto H., Kido Y., Kamijo K., Murano K., Miyake H., Ohkubo M., Kinoshita T., Warizaya M., Iwashita A., Mihara K., Matsuoka N., Hattori K. Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling. Bioorganic and Medicinal Chemistry 2006, 14:1378-1390.
22. Iwashita A., Hattori K., Yamamoto H., Ishida J., Kido Y., Kamijo K., Murano K., Miyake H., Kinoshita T., Warizaya M., Ohkubo M., Matsuoka N., Mutoh S. Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors. FEBS Letters 2005, 1389:1393.
23. Kinoshita T., Nakanishi I., Warizaya M., Iwashita A., Kido Y., Hattori K., Fujii T. Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase. FEBS Letters 2004, 556:43-46.
24. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. Journal of Applied Crystallography 1993, 26:283-291.
25. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Review 2001, 46:3-26.
26. MolinspirationCheminformatics, B., SlovakRepublic.
27. Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. Journal of Computational Chemistry 2009, 30:2785-2791.
28. Miyashiro J., Woods K.W., Park C.H., Liu X., Shi Y., Johnson E.F., Bouska J.J., Olson A.M., Luo Y., Fry E.H., Giranda V.L., Penning T.D. Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly (ADP-ribose) polymerase-1 (PARP-1). Bioorganic and Medicinal Chemistry Letters 2009, 19:4050-4054.
29. Notredame C., Higgins D.G., Heringa J. T-coffee: a novel method for fast and accurate multiple sequence alignment. Journal of molecular biology 2000, 302:205-217.
30. Nwaka S., Hudson A. Innovative lead discovery strategies for tropical diseases. Nature Reviews Drug Discovery 2006, 5:941-955.
31. Penning T.D., Zhu G.D., Gong J., Thomas S., Gandhi V.B., Liu X., Shi Y., Klinghofer V., Johnson E.F., Park C.H., Fry E.H., Donawho C.K., Frost D.J., Buchanan F.G., Bukofzer G.T., Rodriguez L.E., Bontcheva-Diaz V., Bouska J.J., Osterling D.J., Olson A.M., Marsh K.C., Luo Y., Giranda V.L. Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor. Journal of Medicinal Chemistry 2010, 53:3142-3153.
32. Romeiro N.C., Aguirre G., Hernández P., González M., Cerecetto H., Aldana I., Pérez-Silanes S., Monge A., Barreiro E.J., Lima L.M. Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorganic and Medicinal Chemistry 2009, 17:641-652.
33. Ruf A., Mennissier de Murcia J., de Murcia G., Schulz G.E. Structure of the catalytic fragment of poly (AD-ribose) polymerase from chicken. Proceeding of the National Academy of Sciences of the United States of America 1996, 93:7481-7485.
34. Schwede T., Kopp J., Guex N., Peitsch M.C. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Research 2003, 31:3381-3385.
35. Soto J., Rea J., Balderrama M., Toledo J., Soto P., Valda L., Berman J.D. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 2008, 78:210-211.
36. Teixeira M., de Jesus Santos R., Sampaio R., Pontes-de-Carvalho L., dos-Santos W. A simple and reproducible method to obtain large numbers of axenic amastigotes of different Leishmania species. Parasitology Research 2002, 88:963-968.
37. Urbina J.A., Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitology 2003, 19:495-501.
38. Vriend G. What if: a molecular modeling and drug design program. Journal of Molecular Graphics 1990, 8:52-56.
39. Wolber G., Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. Journal of Chemical Information and Modeling 2005, 45:160-169.
40. Yardley V., Croft S.L., de Doncker S., Dujardin J.C., Koirala S., Rijal S., Miranda C., Llanos-Cuentas A., Chappuis F. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. American Journal of Tropical Medicine and Hygiene 2005, 73:272-275.
41. Zhao Y.H., Abraham M.H., Le J., Hersey A., Luscombe C.N., Beck G., Sherborne B., Cooper I. Rate-limited steps of human oral absorption and QSAR studies. Pharmaceutical Research 2002, 19:1446-1457.